Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 107

1.

Association between exhaled nitric oxide and nasal polyposis in severe asthma.

Maniscalco M, Calabrese C, D'Amato M, Guida P, Molino A, Aliani M, De Tullio R, Foschino Barbaro M, Ricciardolo FLM, Carpagnano GE.

Respir Med. 2019 Jun;152:20-24. doi: 10.1016/j.rmed.2019.04.017. Epub 2019 Apr 25.

PMID:
31128605
2.

High-Resolution Computed Tomography (HRCT) Reflects Disease Progression in Patients with Idiopathic Pulmonary Fibrosis (IPF): Relationship with Lung Pathology.

Cocconcelli E, Balestro E, Biondini D, Barbiero G, Polverosi R, Calabrese F, Pezzuto F, Lacedonia D, Rea F, Schiavon M, Bazzan E, Foschino Barbaro MP, Turato G, Spagnolo P, Cosio MG, Saetta M.

J Clin Med. 2019 Mar 22;8(3). pii: E399. doi: 10.3390/jcm8030399.

3.

Severe uncontrolled asthma with bronchiectasis: a pilot study of an emerging phenotype that responds to mepolizumab.

Carpagnano GE, Scioscia G, Lacedonia D, Curradi G, Foschino Barbaro MP.

J Asthma Allergy. 2019 Mar 5;12:83-90. doi: 10.2147/JAA.S196200. eCollection 2019.

4.

Pain Catastrophizing in Childhood Migraine: An Observational Study in a Tertiary Headache Center.

Sciruicchio V, Simeone M, Foschino Barbaro MG, Tanzi RC, Delussi MD, Libro G, D'Agnano D, Basiliana R, de Tommaso M.

Front Neurol. 2019 Feb 15;10:114. doi: 10.3389/fneur.2019.00114. eCollection 2019.

5.

Application of machine learning to predict obstructive sleep apnea syndrome severity.

Mencar C, Gallo C, Mantero M, Tarsia P, Carpagnano GE, Foschino Barbaro MP, Lacedonia D.

Health Informatics J. 2019 Jan 30:1460458218824725. doi: 10.1177/1460458218824725. [Epub ahead of print]

PMID:
30696334
6.

A survey of fungal microbiota in airways of healthy volunteer subjects from Puglia (Apulia), Italy.

Carpagnano GE, Susca A, Scioscia G, Lacedonia D, Cotugno G, Soccio P, Santamaria S, Resta O, Logrieco G, Foschino Barbaro MP.

BMC Infect Dis. 2019 Jan 22;19(1):78. doi: 10.1186/s12879-019-3718-8.

7.

MicroRNA expression profile during different conditions of hypoxia.

Lacedonia D, Scioscia G, Pia Palladino G, Gallo C, Carpagnano GE, Sabato R, Foschino Barbaro MP.

Oncotarget. 2018 Oct 12;9(80):35114-35122. doi: 10.18632/oncotarget.26210. eCollection 2018 Oct 12.

8.

Looking for Airways Periostin in Severe Asthma: Could It Be Useful for Clustering Type 2 Endotype?

Carpagnano GE, Scioscia G, Lacedonia D, Soccio P, Lepore G, Saetta M, Foschino Barbaro MP, Barnes PJ.

Chest. 2018 Nov;154(5):1083-1090. doi: 10.1016/j.chest.2018.08.1032. Epub 2018 Oct 15.

PMID:
30336944
9.

Small airway inflammation and extrafine inhaled corticosteroids plus long-acting beta2-agonists formulations in chronic obstructive pulmonary disease.

Pirina P, Foschino Barbaro MP, Paleari D, Spanevello A.

Respir Med. 2018 Oct;143:74-81. doi: 10.1016/j.rmed.2018.08.013. Epub 2018 Aug 28. Review.

10.

Adherence to GOLD guidelines in real-life COPD management in the Puglia region of Italy.

Palmiotti GA, Lacedonia D, Liotino V, Schino P, Satriano F, Di Napoli PL, Sabato E, Mastrosimone V, Scoditti A, Carone M, Costantino E, Resta E, Attolini E, Foschino Barbaro MP.

Int J Chron Obstruct Pulmon Dis. 2018 Aug 15;13:2455-2462. doi: 10.2147/COPD.S157779. eCollection 2018.

11.

α1-Antitrypsin Polymerizes in Alveolar Macrophages of Smokers With and Without α1-Antitrypsin Deficiency.

Bazzan E, Tinè M, Biondini D, Benetti R, Baraldo S, Turato G, Fagiuoli S, Sonzogni A, Rigobello C, Rea F, Calabrese F, Foschino-Barbaro MP, Miranda E, Lomas DA, Saetta M, Cosio MG.

Chest. 2018 Sep;154(3):607-616. doi: 10.1016/j.chest.2018.04.039. Epub 2018 May 12.

PMID:
29763589
12.

Pretreatment rate of decay in forced vital capacity predicts long-term response to pirfenidone in patients with idiopathic pulmonary fibrosis.

Biondini D, Balestro E, Lacedonia D, Cerri S, Milaneschi R, Luppi F, Cocconcelli E, Bazzan E, Clini E, Foschino Barbaro MP, Gregori D, Cosio MG, Saetta M, Spagnolo P.

Sci Rep. 2018 Apr 13;8(1):5961. doi: 10.1038/s41598-018-24303-4.

13.

Correlation between body mass index and obstructive sleep apnea severity indexes - A retrospective study.

Ciavarella D, Tepedino M, Chimenti C, Troiano G, Mazzotta M, Foschino Barbaro MP, Lo Muzio L, Cassano M.

Am J Otolaryngol. 2018 Jul - Aug;39(4):388-391. doi: 10.1016/j.amjoto.2018.03.026. Epub 2018 Mar 27.

PMID:
29625769
14.

A Real-Life Multicenter National Study on Nintedanib in Severe Idiopathic Pulmonary Fibrosis.

Harari S, Caminati A, Poletti V, Confalonieri M, Gasparini S, Lacedonia D, Luppi F, Pesci A, Sebastiani A, Spagnolo P, Vancheri C, Balestro E, Bonifazi M, Cerri S, De Giacomi F, Della Porta R, Foschino Barbaro MP, Fui A, Pasquinelli P, Rosso R, Tomassetti S, Specchia C, Rottoli P; for the ILDINET (Interstitial Lung Diseases Italian Network).

Respiration. 2018;95(6):433-440. doi: 10.1159/000487711. Epub 2018 Mar 27.

PMID:
29587263
15.

Prevalence of comorbidities in patients with obstructive sleep apnea syndrome, overlap syndrome and obesity hypoventilation syndrome.

Lacedonia D, Carpagnano GE, Patricelli G, Carone M, Gallo C, Caccavo I, Sabato R, Depalo A, Aliani M, Capozzolo A, Foschino Barbaro MP.

Clin Respir J. 2018 May;12(5):1905-1911. doi: 10.1111/crj.12754. Epub 2018 Jan 16.

PMID:
29227046
16.

New non invasive ventilator strategy applied to COPD patients in acute ventilator failure.

Carpagnano GE, Sabato R, Lacedonia D, Di Gioia R, Saliani V, Vincenzi U, Foschino-Barbaro MP.

Pulm Pharmacol Ther. 2017 Oct;46:64-68. doi: 10.1016/j.pupt.2017.08.009. Epub 2017 Aug 17.

PMID:
28823948
17.

Expression profiling of miRNA-145 and miRNA-338 in serum and sputum of patients with COPD, asthma, and asthma-COPD overlap syndrome phenotype.

Lacedonia D, Palladino GP, Foschino-Barbaro MP, Scioscia G, Carpagnano GE.

Int J Chron Obstruct Pulmon Dis. 2017 Jun 23;12:1811-1817. doi: 10.2147/COPD.S130616. eCollection 2017.

18.

A New SERPINA-1 Missense Mutation Associated with Alpha-1 Antitrypsin Deficiency and Bronchiectasis.

Carpagnano GE, Santacroce R, Palmiotti GA, Leccese A, Giuffreda E, Margaglione M, Foschino Barbaro MP, Aliberti S, Lacedonia D.

Lung. 2017 Oct;195(5):679-682. doi: 10.1007/s00408-017-0033-2. Epub 2017 Jul 1.

PMID:
28668972
19.

Asthma management in a specialist setting: Results of an Italian Respiratory Society survey.

Braido F, Baiardini I, Alleri P, Bacci E, Barbetta C, Bellocchia M, Benfante A, Blasi F, Bucca C, Busceti MT, Centanni S, Colanardi MC, Contoli M, Corsico A, D'Amato M, Di Marco F, Marco D, Ferrari M, Florio G, Fois AG, Foschino Barbaro MP, Silvia G, Girbino G, Grosso A, Latorre M, Maniscalco S, Mazza F, Mereu C, Molinengo G, Ora J, Paggiaro P, Patella V, Pelaia G, Pirina P, Proietto A, Rogliani P, Santus P, Scichilone N, Simioli F, Solidoro P, Terraneo S, Zuccon U, Canonica GW.

Pulm Pharmacol Ther. 2017 Jun;44:83-87. doi: 10.1016/j.pupt.2017.03.013. Epub 2017 Mar 21.

PMID:
28341462
20.

Exhaled breath temperature measurement: influence of circadian rhythm.

Carpagnano GE, Lacedonia D, Malerba M, Martinelli D, Cotugno G, Foschino-Barbaro MP.

J Biol Regul Homeost Agents. 2017 Jan-Mar;31(1):229-235.

PMID:
28337897
21.

New panel of microsatellite alterations detectable in the EBC for lung cancer prognosis.

Carpagnano GE, Lacedonia D, Crisetti E, Martinelli D, Foschino-Barbaro MP.

J Cancer. 2016 Nov 25;7(15):2266-2269. eCollection 2016.

22.

Validation of the Exhaled Breath Temperature Measure: Reference Values in Healthy Subjects.

Carpagnano GE, Foschino-Barbaro MP, Crocetta C, Lacedonia D, Saliani V, Zoppo LD, Barnes PJ.

Chest. 2017 Apr;151(4):855-860. doi: 10.1016/j.chest.2016.11.013. Epub 2016 Nov 23.

PMID:
27889360
23.

Effects of omalizumab in severe asthmatics across ages: A real life Italian experience.

Sposato B, Scalese M, Latorre M, Scichilone N, Matucci A, Milanese M, Masieri S, Rolla G, Steinhilber G, Rosati Y, Vultaggio A, Folletti I, Baglioni S, Bargagli E, Di Tomassi M, Pio R, Pio A, Maccari U, Maggiorelli C, Migliorini MG, Vignale L, Pulerà N, Carpagnano GE, Foschino Barbaro MP, Perrella A, Paggiaro PL.

Respir Med. 2016 Oct;119:141-149. doi: 10.1016/j.rmed.2016.09.005. Epub 2016 Sep 4.

24.

How strong is the association between IPF and lung cancer? An answer from airway's DNA.

Carpagnano GE, Lacedonia D, Soccio P, Caccavo I, Patricelli G, Foschino Barbaro MP.

Med Oncol. 2016 Nov;33(11):119. doi: 10.1007/s12032-016-0835-8. Epub 2016 Sep 29.

PMID:
27688240
25.

Different dyspnoea perception in COPD patients with frequent and infrequent exacerbations.

Scioscia G, Blanco I, Arismendi E, Burgos F, Gistau C, Foschino Barbaro MP, Celli B, O'Donnell DE, Agustí A.

Thorax. 2017 Feb;72(2):117-121. doi: 10.1136/thoraxjnl-2016-208332. Epub 2016 Sep 1.

PMID:
27586869
26.

Evaluation of adiponectin profile in Italian patients affected by obstructive sleep apnea syndrome.

Lacedonia D, Nigro E, Matera MG, Scudiero O, Monaco ML, Polito R, Carpagnano GE, Foschino Barbaro MP, Mazzarella G, Bianco A, Daniele A.

Pulm Pharmacol Ther. 2016 Oct;40:104-8. doi: 10.1016/j.pupt.2016.07.008. Epub 2016 Jul 25.

PMID:
27470682
27.

Viral colonization in exhaled breath condensate of lung cancer patients: Possible role of EBV and CMV.

Carpagnano GE, Lacedonia D, Natalicchio MI, Cotugno G, Zoppo L, Martinelli D, Antonetti R, Foschino-Barbaro MP.

Clin Respir J. 2018 Feb;12(2):418-424. doi: 10.1111/crj.12531. Epub 2016 Jul 25.

PMID:
27421948
28.

Analysis of the fungal microbiome in exhaled breath condensate of patients with asthma.

Carpagnano GE, Malerba M, Lacedonia D, Susca A, Logrieco A, Carone M, Cotugno G, Palmiotti GA, Foschino-Barbaro MP.

Allergy Asthma Proc. 2016 May;37(3):41-6. doi: 10.2500/aap.2016.37.3943.

PMID:
27178886
29.

Study of mitochondrial DNA alteration in the exhaled breath condensate of patients affected by obstructive lung diseases.

Carpagnano GE, Lacedonia D, Carone M, Soccio P, Cotugno G, Palmiotti GA, Scioscia G, Foschino Barbaro MP.

J Breath Res. 2016 Apr 11;10(2):026005. doi: 10.1088/1752-7155/10/2/026005.

PMID:
27063576
30.

Microparticles in sputum of COPD patients: a potential biomarker of the disease?

Lacedonia D, Carpagnano GE, Trotta T, Palladino GP, Panaro MA, Zoppo LD, Foschino Barbaro MP, Porro C.

Int J Chron Obstruct Pulmon Dis. 2016 Mar 14;11:527-33. doi: 10.2147/COPD.S99547. eCollection 2016.

31.

Is the Exhaled Breath Temperature Sensitive to Cigarette Smoking?

Carpagnano GE, Ruggieri C, Scioscia G, Storto MM, Zoppo L, Foschino-Barbaro MP.

COPD. 2016 Oct;13(5):642-6. doi: 10.3109/15412555.2016.1143458. Epub 2016 Mar 2.

PMID:
26934668
32.

Analysis of mitochondrial DNA alteration in new phenotype ACOS.

Carpagnano GE, Lacedonia D, Malerba M, Palmiotti GA, Cotugno G, Carone M, Foschino-Barbaro MP.

BMC Pulm Med. 2016 Feb 12;16:31. doi: 10.1186/s12890-016-0192-6.

33.

Tissue Doppler Imaging predicts central sleep apnea in patients with chronic heart failure: data from the Daunia Registry.

Correale M, Brunetti ND, Forte L, Passero T, Monaco I, Ferraretti A, Totaro A, Carpagnano GE, Foschino Barbaro MP, Di Biase M, Lacedonia D.

Eur J Clin Invest. 2015 Nov;45(11):1153-60. doi: 10.1111/eci.12520. Epub 2015 Sep 13.

PMID:
26365893
34.

Is the exhaled breath temperature in lung cancer influenced by airways neoangiogenesis or by inflammation?

Carpagnano GE, Lacedonia D, Spanevello A, Cotugno G, Saliani V, Martinelli D, Foschino-Barbaro MP.

Med Oncol. 2015 Oct;32(10):237. doi: 10.1007/s12032-015-0681-0. Epub 2015 Sep 1.

PMID:
26323590
35.

Mitochondrial DNA alteration in obstructive sleep apnea.

Lacedonia D, Carpagnano GE, Crisetti E, Cotugno G, Palladino GP, Patricelli G, Sabato R, Foschino Barbaro MP.

Respir Res. 2015 Apr 7;16:47. doi: 10.1186/s12931-015-0205-7.

36.

HIV-associated pulmonary arterial hypertension: from bedside to the future.

Correale M, Palmiotti GA, Lo Storto MM, Montrone D, Foschino Barbaro MP, Di Biase M, Lacedonia D.

Eur J Clin Invest. 2015 May;45(5):515-28. doi: 10.1111/eci.12427. Epub 2015 Mar 24. Review.

PMID:
25715739
37.

Health and social impacts of COPD and the problem of under-diagnosis.

Carlone S, Balbi B, Bezzi M, Brunori M, Calabro S, Foschino Barbaro MP, Micheletto C, Privitera S, Torchio R, Schino P, Vianello A.

Multidiscip Respir Med. 2014 Dec 6;9(1):63. doi: 10.1186/2049-6958-9-63. eCollection 2014. Review.

38.

Disability in moderate chronic obstructive pulmonary disease: prevalence, burden and assessment - results from a real-life study.

Braido F, Baiardini I, Scichilone N, Sorino C, Di Marco F, Corsico A, Santus P, Girbino G, Di Maria G, Mereu C, Sabato E, Foschino Barbaro MP, Cuttitta G, Zolezzi A, Bucca C, Balestracci S, Canonica GW.

Respiration. 2015;89(2):100-6. doi: 10.1159/000368365. Epub 2015 Jan 21.

39.

Fluticasone propionate/formoterol: a fixed-combination therapy with flexible dosage.

Papi A, Blasi F, Canonica GW, Cazzola M, Centanni S, Foschino Barbaro MP, Melani AS, Paggiaro P, Ricciardolo F, Rossi A, Scichilone N.

Eur J Intern Med. 2014 Oct;25(8):695-700. doi: 10.1016/j.ejim.2014.06.022. Epub 2014 Jul 19. Review.

PMID:
25051902
40.

Exhaled HPV infection in lung cancer: role of MA at 3p.

Carpagnano GE, Lacedonia D, Crisetti E, Palladino GP, Saliani V, Zoppo LD, Antonetti R, Natalicchio I, Foschino-Barbaro MP.

Arch Med Res. 2014 Jul;45(5):383-7. doi: 10.1016/j.arcmed.2014.06.006. Epub 2014 Jun 21.

PMID:
24962429
41.

Exhaled breath temperature in NSCLC: could be a new non-invasive marker?

Carpagnano GE, Lacedonia D, Spanevello A, Martinelli D, Saliani V, Ruggieri C, Foschino-Barbaro MP.

Med Oncol. 2014 May;31(5):952. doi: 10.1007/s12032-014-0952-1. Epub 2014 Apr 11.

PMID:
24722795
42.

Aspergillus spp. colonization in exhaled breath condensate of lung cancer patients from Puglia Region of Italy.

Carpagnano GE, Lacedonia D, Palladino GP, Logrieco G, Crisetti E, Susca A, Logrieco A, Foschino-Barbaro MP.

BMC Pulm Med. 2014 Feb 18;14:22. doi: 10.1186/1471-2466-14-22.

43.

Role of vasoactive intestinal peptide in chronic obstructive pulmonary disease with pulmonary hypertension.

Lacedonia D, Valerio G, Palladino GP, Carpagnano GE, Correale M, Di Biase M, Foschino Barbaro MP.

Rejuvenation Res. 2014 Feb;17(1):33-9. doi: 10.1089/rej.2013.1478.

PMID:
24228853
44.

Effect of endothelin inhibition on lung fibroblasts on patients with systemic sclerosis.

Corrado A, Neve A, Costantino E, Palladino GP, Foschino Barbaro MP, Cantatore FP.

Minerva Med. 2013 Oct;104(5):505-17.

PMID:
24101108
45.

Daytime PaO2 in OSAS, COPD and the combination of the two (overlap syndrome).

Lacedonia D, Carpagnano GE, Aliani M, Sabato R, Foschino Barbaro MP, Spanevello A, Carone M, Fanfulla F.

Respir Med. 2013 Feb;107(2):310-6. doi: 10.1016/j.rmed.2012.10.012. Epub 2012 Nov 7.

46.

Exhaled matrix metalloproteinase-9 in lung cancer.

Carpagnano GE, Palladino GP, Martinelli D, Lacedonia D, Orlando S, Foschino-Barbaro MP.

Rejuvenation Res. 2012 Aug;15(4):359-65. doi: 10.1089/rej.2011.1254.

PMID:
22877564
47.

Could neutrophilic airway inflammation in obese people be more due to obstructive sleep apnoea syndrome than to asthma?

Carpagnano GE, Foschino-Barbaro MP, Carratu P, Lacedonia D, Resta O.

Eur Respir J. 2012 Jun;39(6):1547-9. doi: 10.1183/09031936.00184111. No abstract available.

48.

Microsatellite alterations and cell-free DNA analysis: could they increase the cytology sensitivity in the diagnosis of malignant pleural effusion?

Carpagnano GE, Costantino E, Palladino GP, Lacedonia D, Martinelli D, Orlando S, Foschino-Barbaro MP.

Rejuvenation Res. 2012 Jun;15(3):265-73. doi: 10.1089/rej.2011.1260. Epub 2012 May 2.

PMID:
22551519
49.

Microsatellite alterations at 3p and 19q in EBC DNA of smokers: are they reversible after smoking cessation?

Carpagnano GE, Lacedonia D, Palladino GP, Foschino Barbaro MP.

Eur Respir J. 2011 Dec;38(6):1477-80. doi: 10.1183/09031936.00032011. No abstract available.

50.

Could exhaled ferritin and SOD be used as markers for lung cancer and prognosis prediction purposes?

Carpagnano GE, Lacedonia D, Palladino GP, Koutelou A, Martinelli D, Orlando S, Foschino-Barbaro MP.

Eur J Clin Invest. 2012 May;42(5):478-86. doi: 10.1111/j.1365-2362.2011.02603.x. Epub 2011 Sep 28.

PMID:
21955247

Supplemental Content

Loading ...
Support Center